• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Axsome Therapeutics Inc.

    4/24/26 5:02:38 PM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AXSM alert in real time by email
    DEFA14A 1 axsm_2026_april_proxy_-_.htm DEFA14A DEFA14A

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of

    the Securities Exchange Act of 1934 (Amendment No.)

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐

    Definitive Proxy Statement

    ☒

    Definitive Additional Materials

    ☐

    Soliciting Material under §240.14a-12

     

    AXSOME THERAPEUTICS, INC.

    (Name of Registrant as Specified In Its Charter)

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box):

     

    ☒

    No fee required.

    ☐

    Fee paid previously with preliminary materials.

    ☐

    Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     

     


     

    img423755_0.jpg

    Your Vote Counts! AXSOME THERAPEUTICS, INC. 2026 Annual Meeting Vote by June 4, 2026 11:59 PM ET axsome AXSOME THERAPEUTICS, INC. ONE WORLD TRADE CENTER, 29TH FLOOR NEW YORK, NY 10007 V91337-P50476 You invested in AXSOME THERAPEUTICS, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on June 5, 2026. Get informed before you vote View the Notice, Proxy Statement and Annual Report online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 22, 2026. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy pv For complete information and to vote, visit www.ProxyVote.com Control # Smartphone users Point your camera here and vote without entering a control number Vote Virtually at the Meeting* June 5, 2026 9:00 AM EDT Virtually at: www.virtualshareholdermeeting.com/AXSM2026*Please check the meeting materials for any special requirements for meeting attendance.


     

    img423755_1.jpg

    Vote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. Voting Items 1. Election of Directors Nominees: 01) Mark Saad 02) Susan Mahony, Ph.D., MBA 2. To ratify the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026. Board Recommends For For For 3. To approve, by non-binding advisory vote, the compensation of our named executive officers. NOTE: Such other business as may properly come before the meeting or any adjournment thereof. For Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. V91338-P50476


    Get the next $AXSM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AXSM

    DatePrice TargetRatingAnalyst
    2/24/2026$230.00Outperform
    Wolfe Research
    1/8/2026$204.00Overweight → Equal-Weight
    Morgan Stanley
    10/1/2025$179.00Buy
    B. Riley Securities
    9/3/2025$163.00Overweight
    Wells Fargo
    7/3/2025$190.00Overweight
    Morgan Stanley
    6/3/2025$185.00Outperform
    Oppenheimer
    4/7/2025$200.00Buy
    Jefferies
    2/11/2025$176.00Buy
    Deutsche Bank
    More analyst ratings

    $AXSM
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for AUVELITY issued to AXSOME THERAPEUTICS, INC.

    Submission status for AXSOME THERAPEUTICS, INC.'s drug AUVELITY (ORIG-1) with active ingredient DEXTROMETHORPHAN HYDROBROMIDE AND BUPROPION HYDROCHLORIDE has changed to 'Approval' on 08/18/2022. Application Category: NDA, Application Number: 215430, Application Classification: Type 3 - New Dosage Form and Type 4 - New Combination

    8/19/22 12:36:14 PM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AXSM
    SEC Filings

    View All

    $AXSM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Axsome Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Axsome Therapeutics, Inc. (0001579428) (Filer)

    6/3/26 9:04:18 AM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Axsome Therapeutics Inc.

    10-Q - Axsome Therapeutics, Inc. (0001579428) (Filer)

    5/4/26 5:04:24 PM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Axsome Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

    8-K - Axsome Therapeutics, Inc. (0001579428) (Filer)

    5/4/26 7:07:33 AM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wolfe Research initiated coverage on Axsome Therapeutics with a new price target

    Wolfe Research initiated coverage of Axsome Therapeutics with a rating of Outperform and set a new price target of $230.00

    2/24/26 7:45:48 AM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Axsome Therapeutics downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Axsome Therapeutics from Overweight to Equal-Weight and set a new price target of $204.00

    1/8/26 8:36:26 AM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    B. Riley Securities initiated coverage on Axsome Therapeutics with a new price target

    B. Riley Securities initiated coverage of Axsome Therapeutics with a rating of Buy and set a new price target of $179.00

    10/1/25 8:44:08 AM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AXSM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Coleman Mark bought $200,466 worth of shares (1,575 units at $127.28), increasing direct ownership by 3% to 48,212 units (SEC Form 4)

    4 - Axsome Therapeutics, Inc. (0001579428) (Issuer)

    9/9/25 8:11:58 PM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AXSM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Axsome Therapeutics Presents New SYMBRAVO® Data at the Americal Headache Society (AHS) 68th Annual Scientific Meeting

    NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced presentations of new SYMBRAVO® data at the Americal Headache Society (AHS) 68th Annual Scientific Meeting being held from June 4-7 in Orlando, FL. Details of the presentations are as follows: Title: SYMBRAVO (MoSEIC™ meloxicam and rizatriptan) for the Acute Treatment of Migraine: Post-hoc Composite Efficacy and Return to Function Endpoint Analysis from MOMENTUMPresentation Date and Time: Thursday, June 4, 6:00 - 7:30 p.m. ETLead Author: Richard Lipton, MD, Professor of Neurology and D

    6/4/26 7:00:00 AM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Axsome Therapeutics Announces Settlement Resolving All SUNOSI® (solriamfetol) Patent Litigation

    NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it has resolved all patent litigation related to Axsome's product SUNOSI (solriamfetol). The litigations resulted from submission of Abbreviated New Drug Applications to the U.S. Food and Drug Administration by companies seeking approval to market a generic version of SUNOSI in the United States. Axsome resolved all outstanding SUNOSI patent litigation upon entering into a settlement agreement with the only remaining first-to-file generic applicant with pending patent lit

    6/3/26 7:00:00 AM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Axsome Therapeutics Partners with the Headache Alliance to Highlight the Impact of Migraine During Migraine and Headache Awareness Month

    NEW YORK, June 01, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today highlighted its commitment to the migraine community by supporting educational initiatives during Migraine and Headache Awareness Month this June. "People living with migraine and headache disorders deserve to be seen, believed, and supported with information and care that reflect the seriousness of these diseases," said Julienne Verdi, Executive Director of The Headache Alliance and the Alliance for Headache Disorders Advocacy. "Awareness campaigns like Headache in the City help the public bett

    6/1/26 7:00:00 AM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AXSM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Coleman Mark sold $4,019,470 worth of shares (17,537 units at $229.20) as part of a pre-agreed trading plan, decreasing direct ownership by 37% to 29,603 units (SEC Form 4)

    4 - Axsome Therapeutics, Inc. (0001579428) (Issuer)

    6/2/26 7:00:04 PM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Operating Officer Jacobson Mark L. exercised 4,750 shares at a strike of $12.95 and sold $1,082,771 worth of shares (4,750 units at $227.95) as part of a pre-agreed trading plan (SEC Form 4)

    4 - Axsome Therapeutics, Inc. (0001579428) (Issuer)

    5/5/26 8:34:35 PM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Operating Officer Jacobson Mark L.

    4 - Axsome Therapeutics, Inc. (0001579428) (Issuer)

    4/23/26 9:02:45 PM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AXSM
    Financials

    Live finance-specific insights

    View All

    Axsome Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

    Total 1Q 2026 net product revenue of $191.2 million, representing 57% year-over-year growth AUVELITY® 1Q 2026 net product sales of $153.2 million, representing 59% year-over-year growth SUNOSI® 1Q 2026 net product revenue of $33.9 million, representing 34% year-over-year growth SYMBRAVO® 1Q 2026 net product sales of $4.1 million AUVELITY approved for the treatment of agitation associated with dementia due to Alzheimer's disease NDA for AXS-12 for the treatment of cataplexy in narcolepsy submitted to the FDA AXS-20 (balipodect), potentially first-in-class, pre-Phase 3, PDE10A inhibitor for schizophrenia and Tourette syndrome, added to pipeline Company to host conference call today at 8

    5/4/26 7:00:00 AM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Axsome Therapeutics Hosts AUVELITY® FDA Approval Investor Event Featuring Expert Thought Leader

    NEW YORK, May 01, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, will host a virtual investor event and conference call today at 8:00 AM Eastern Time to discuss the U.S. Food and Drug Administration (FDA) approval of AUVELITY® (dextromethorphan HBr and bupropion HCl) for the treatment of agitation associated with dementia due to Alzheimer's disease.1 AUVELITY is a first-in-class treatment for Alzheimer's disease agitation which targets the N-methyl D-aspartate (NMDA) and sigma-1 receptors. On the call, Dr. Jeffrey Cummings, Chambers-Grundy Professor of Brain Science

    5/1/26 7:15:00 AM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Axsome Therapeutics Announces FDA Approval of AUVELITY® (dextromethorphan HBr and bupropion HCl) for the Treatment of Agitation Associated with Dementia due to Alzheimer's Disease

    AUVELITY is a first-in-class treatment, which targets the NMDA and sigma-1 receptors, approved for agitation associated with dementia due to Alzheimer's disease  The safety and tolerability profile of AUVELITY in agitation associated with dementia due to Alzheimer's disease has been established across short-term and long-term trials AUVELITY was developed with FDA Breakthrough Therapy designation and evaluated by the FDA under Priority Review Company to host webcast Friday, May 1, at 8:00 AM Eastern Time NEW YORK, April 30, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) di

    4/30/26 2:06:04 PM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AXSM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Axsome Therapeutics Inc. (Amendment)

    SC 13G/A - Axsome Therapeutics, Inc. (0001579428) (Subject)

    2/14/24 3:46:49 PM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Axsome Therapeutics Inc. (Amendment)

    SC 13G/A - Axsome Therapeutics, Inc. (0001579428) (Subject)

    2/14/24 7:26:39 AM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Axsome Therapeutics Inc. (Amendment)

    SC 13G/A - Axsome Therapeutics, Inc. (0001579428) (Subject)

    2/13/24 4:58:57 PM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AXSM
    Leadership Updates

    Live Leadership Updates

    View All

    Axsome Therapeutics, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; December 7, 2023 deadline.

    Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Nov. 28, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Axsome Therapeutics, Inc. ("Axsome" or "the Company") (NASDAQ:AXSM) investors that a lawsuit filed on behalf of investors that purchased Axsome securities between May 10, 2021 and April 22, 2022, inclusive (the "Class Period") Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options fo

    11/28/23 6:51:20 PM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Axsome Therapeutics Appoints Dr. Sue Mahony to its Board of Directors

    NEW YORK, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Susan Mahony, PhD, has been appointed to Axsome's board of directors, effective immediately. Dr. Mahony most recently served on the board of directors of Horizon Therapeutics from 2019 until its acquisition by Amgen in October 2023. She was formerly Senior Vice President of Eli Lilly and Company and President of Lilly Oncology, where under her leadership, the business unit evolved from one to five marketed medicines. At Lilly, she held leadership position

    10/11/23 7:00:00 AM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care